Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Podobne zapisy

• Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
  od: Robert Brown, i wsp.
  Wydane: (2022-06-01)
• Restoration and functional analysis of the SGI1 resolution system – SGI1 multimers are eliminated by the reactivated resolution
  od: Alexandra Veress, i wsp.
  Wydane: (2025-07-01)
• A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
  od: Marie Sébert, i wsp.
  Wydane: (2019-08-01)
• P765: UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS)
  od: C. D. DiNardo, i wsp.
  Wydane: (2022-06-01)
• Treatment Patterns and Outcomes of Patients With Myelodysplastic Syndrome (MDS) by IPSS-R Scores at Academic Cancer Centers
  od: Connor Willis, i wsp.
  Wydane: (2025-01-01)